Organon

Visit Organon at the @ASRM_org 2026 Scientific Congress & Expo to see how we’re helping to expand access to fertility treatments for aspiring families. Discover our fertility medication savings program and learn how we’re driving progress with long-time collaborator @ReUniteRx with a focus on transparent pricing, lower out-of-pocket costs, and fewer financial barriers. We're excited to share more about this program and showcase our ongoing commitment to providing affordable fertility care options. Come find us at Booth #837 from October 26-28 in Baltimore, MD to learn more. #ASRM2026 #FertilityJourney #HereForHerHealth

For US audiences only. Organon today announced positive interim Phase 3 study results that assessed extended duration of use for its licensed contraceptive product, which will be presented by Sebela Women’s Health at the 2026 Society of Family Planning (SFP) Annual Meeting on October 17 in San Francisco, CA. Organon holds exclusive global licensing rights to this product. We recognize the importance of continuing research around contraception to help potentially expand the available options. Learn more at ogn.llc/6015at9m5 #Contraception #BirthControl

Join us as we lead the conversation around #osteoporosis and continue our work supporting access to treatments at the American Society for Bone and Mineral Research (@ASBMR) Annual Meeting from October 9-11 in Boston, MA. Visit us at booth #112 to learn more. #BoneHealth

For US audiences only. Organon today announced that a new real-world analysis of patients with atopic dermatitis (AD) using our topical therapy will be on display at the 2026 Fall Clinical Dermatology Conference. “Real-world data can provide important insight into how patients with AD respond to treatment and how their disease is managed in everyday clinical practice,” said Cameron West, MD, lead author of the analysis. Learn more: ogn.llc/6017aYAcL #OrganonDermatology

#RegulatoryNews: Organon today announced the U.S. Food & Drug Administration has accepted for review Sebela Women’s Health’s supplemental new drug application for an extended duration of use for one of its contraceptive products. Organon holds exclusive global licensing rights to this product. PDUFA action anticipated in the second quarter of 2027. This announcement affirms Organon’s ongoing commitment to broaden birth control options for women and access to products that support their needs. Learn more at ogn.llc/6010awCZQ Intended for US audiences only. #Contraception #BirthControl

For US audiences only. Organon has announced the opening of a REMS program to help facilitate the safe use of our contraceptive product. The program enables healthcare providers, healthcare settings, and eligible specialty pharmacies to complete certification and enrollment activities in advance of an anticipated launch in late 2026. Read the full release here -> ogn.llc/6017aHKpt

For US audiences only. This week Organon presented new analysis of Phase 3 data at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting for one of our dermatology treatments for atopic dermatitis. The findings demonstrate improvements in skin clearance and disease severity across subgroups of pediatric and adult patients. Read more: ogn.llc/6017vAhF3 #OrganonDermatology #SPD2026

An estimated 259 million women globally lack access to modern methods of contraception. Closing that gap requires bold investment, smarter systems, and partnerships built for impact. Organon has committed more than $1.3 million to the @UNFPA across nine country programs in Latin America, Africa, and Asia — funding locally driven solutions that train frontline health workers, strengthen supply chains, and break down the systemic barriers that impact contraceptive choice. We're honored to stand alongside UNFPA in this work — and to further our commitment to a better and healthier every day for every woman. Read the full update → ogn.llc/6011vf7PJ #HereForHerHealth #ReproductiveHealth #ContraceptiveAccess

#NEWS: Organon and @SamsungBioepis announced the expansion of their current development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada and Australia to a Samsung Bioepis biosimilar. The amended agreements deepen the Organon and Samsung Bioepis collaboration across multiple therapeutic areas. This also reinforces the companies’ commitment to potentially more affordable treatment options that can help expand access to important medicines for patients and reduce spending pressures on healthcare systems. #OrganonBiosimilars #AllInOnBiosimilars

We're excited to announce the latest recipients of Organon's 2026 Her Health Grants! Chosen from more than 70 applicants, 8 NGOs and non-profit organizations across 7 countries have been selected in this second wave of the 2026 Her Health Grants. They will receive funding from Organon's Global ESG & Corporate Responsibility team to expand their reach and deepen impact across women's health — focusing on areas that affect women uniquely, disproportionately, or differently. Meet our awardees: Arthritis Consumer Experts Fundación Valle del Lili The Fibroid Foundation UNFPA Brazil Asociatia SEXUL vs BARZA Family Equality Ipas Development Foundation UNFPA Ecuador These organizations exemplify the community-driven solutions that move the needle on women's health worldwide and align with our vision of a healthier every day for every woman. We’re thankful for these organizations’ dedication and commitment to bringing about real change. #HerHealthGrants #HereForHerHealth #ESG #CorporateResponsibility

For US audiences only. We’re excited to present new analysis of pooled Phase 3 data at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting that evaluates efficacy and safety for one of our dermatology treatments for atopic dermatitis across age groups in adults and pediatric patients 2 years of age and older. Read more: bit.ly/4w0eOS3 #OrganonDermatology #SPD2026

At #ESHRE2026, we are proud to stand alongside the global scientific community helping to advance the field of fertility care. As research continues to evolve, forums like ESHRE play an essential role in strengthening collaboration, deepening scientific understanding, and informing evidence‑based practice. Improving access to fertility care remains a critical global need, and our commitment is clear: to support the science, dialogue, and partnerships that contribute to better health outcomes for women everywhere. #ReproductiveHealth #FertilityCare #WomensHealth #Organon

Intended for US audiences only. Organon has completed a global licensing agreement with Sebela Pharmaceuticals for their contraceptive product, expanding Organon’s portfolio of long-acting reversible contraception options. This agreement underscores our commitment to broadening contraceptive choice and delivering options that meet women’s needs. By building on our legacy in contraception, we continue to focus on expanding access to important options that support women’s health. Learn more: ogn.llc/6016vWW6j

For too long the impact of menstrual pain has been underestimated. Dysmenorrhea is one of the most common and undertreated women’s health conditions, affecting millions globally and significantly impacting daily activities, education, work, and overall well-being. Today, Organon received regulatory approval in Japan for one of its products for dysmenorrhea. This milestone highlights Organon’s commitment to addressing this long‑standing unmet need and brings greater recognition to this condition, expanding awareness and access for women seeking support. We are proud of the collaboration and dedication of our colleagues in Japan and across the organization who helped make this achievement possible. #Dysmenorrhea #WomensHealth #HereForHerHealth

Intended for US audiences only. Organon has received U.S. FDA approval to expand the indications of one of its biosimilars to now include treatment of certain patients with Cytokine Release Syndrome (CRS) and pediatric COVID-19. These expanded indications reflect continued progress in broadening access to important treatment options for patients with critical care needs. Learn more about the expanded indications: ogn.llc/6012vgipC #OrganonBiosimilars

Intended for US audiences only. Organon will be presenting new health economics and outcomes research at ISPOR 2026. Across eight accepted abstracts, our latest data highlight critical issues shaping healthcare today including contraception affordability, biosimilar adoption, and access-focused analyses across women’s health and general medicines. These studies reflect our commitment to generating real-world evidence rooted in lived experiences, helping inform better decision-making and ultimately improving outcomes for patients and providers alike. Insights include: • Cost-effectiveness and budget impact of contraceptive options in international markets • Access and affordability considerations for innovative dermatology treatments in the U.S. • Real-world analyses of biosimilar adoption and healthcare system impact • Patient referral patterns and healthcare utilization in neurology Health economics and outcomes research plays a vital role in ensuring the right treatments reach the right patients—sustainably and equitably. Learn more here: ogn.llc/6018vTTsn

We’re honored to join the @acog in Washington, DC, as it celebrates its 75th anniversary. Visit us at booths #933 and #849 Marking another year at this important meeting, we’re presenting recent data highlighting a Phase 3, multicenter, open label study evaluating extended use of our long-acting contraceptive option. Join us for our poster session on May 2, 8:00–9:00 AM ET in Hall DE. We’re proud to gather with the healthcare community at #ACOG2026, including as a presenting sponsor of the Anniversary Gala. Intended for US audiences only.

#NEWS We are proud to announce with @HenliusBiotech that the European Commission has approved the first biosimilar in Europe for patients with certain types of breast cancer. Learn more about this milestone: organon.com/news/european-co… Intended for US audiences only